BlackRock, Inc. 13D and 13G filings for Cue Biopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-07 5:09 pm Sale | 2024-01-31 | 13G | Cue Biopharma, Inc. CUE | BlackRock Inc. BLK | 2,247,978 4.980% | -90,787 (-3.88%) | Filing |
| 2024-01-31 2:08 pm Purchase | 2023-12-31 | 13G | Cue Biopharma, Inc. CUE | BlackRock Inc. BLK | 2,338,765 5.200% | 1,506,840 (+181.13%) | Filing |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Cue Biopharma, Inc. CUE | BlackRock Inc. BLK | 831,925 2.400% | -1,458,344 (-63.68%) | Filing |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | Cue Biopharma, Inc. CUE | BlackRock Inc. BLK | 2,290,269 7.200% | 127,291 (+5.88%) | Filing |
| 2021-01-29 09:56 am Purchase | 2020-12-31 | 13G | Cue Biopharma, Inc. CUE | BlackRock Inc. BLK | 2,162,978 7.100% | 775,309 (+55.87%) | Filing |
| 2020-02-07 08:45 am Purchase | 2019-12-31 | 13G | Cue Biopharma, Inc. CUE | BlackRock Inc. BLK | 1,387,669 6.000% | 1,387,669 (New Position) | Filing |